New pill tested to control advanced breast cancer

NCT ID NCT03284957

Summary

This study tested a new oral drug called amcenestrant for postmenopausal women with advanced, estrogen receptor-positive breast cancer. The main goals were to find safe doses and see if the drug, given alone or with other cancer therapies, could help control the disease. The trial was terminated early and enrolled 136 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fred Hutchinson Cancer Center- Site Number : 8400001

    Seattle, Washington, 98109, United States

  • Investigational Site Number : 0560001

    Leuven, 3000, Belgium

  • Investigational Site Number : 1240002

    Toronto, Ontario, M4N 3M5, Canada

  • Investigational Site Number : 1240003

    Vancouver, British Columbia, V5Z 1L3, Canada

  • Investigational Site Number : 1240004

    Edmonton, Alberta, T6G 1Z2, Canada

  • Investigational Site Number : 2030001

    Prague, 128 08, Czechia

  • Investigational Site Number : 2030002

    Brno, 656 53, Czechia

  • Investigational Site Number : 2030003

    Prague, 140 59, Czechia

  • Investigational Site Number : 2500001

    Saint-Herblain, 44805, France

  • Investigational Site Number : 2500002

    Bordeaux, 33076, France

  • Investigational Site Number : 2500003

    Lyon, 69373, France

  • Investigational Site Number : 2500004

    Villejuif, 94805, France

  • Investigational Site Number : 2500005

    Lille, 59000, France

  • Investigational Site Number : 3800003

    Milan, Milano, 20141, Italy

  • Investigational Site Number : 6160004

    Gdynia, Pomeranian Voivodeship, 81-519, Poland

  • Investigational Site Number : 6200001

    Lisbon, 1649-035, Portugal

  • Investigational Site Number : 6200002

    Lisbon, 1998-018, Portugal

  • Investigational Site Number : 7240001

    Madrid, 28041, Spain

  • Investigational Site Number : 7240002

    Madrid, 28050, Spain

  • Investigational Site Number : 7240007

    Madrid, 28034, Spain

  • Investigational Site Number : 8260002

    Cardiff, Cardiff [Caerdydd Gb-crd], CF14 2TL, United Kingdom

  • Investigational Site Number : 8260003

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

  • Massachusetts General Hospital- Site Number : 8400002

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue- Site Number : 8400003

    New York, New York, 10065, United States

  • University of Colorado - Anschutz Medical Campus- Site Number : 8400005

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.